Skip to main content
Clinical Trials/NCT03993977
NCT03993977
Withdrawn
Not Applicable

ROTEM-guided Transfusion Protocol Versus Standard Care in Attempt to Reduce Blood Transfusions in Potentially Curative Major Abdominal and Urological Oncological Surgery

Tampere University Hospital1 site in 1 countryMay 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Blood Loss, Surgical
Sponsor
Tampere University Hospital
Locations
1
Primary Endpoint
Number of transfused red blood cell (RBC) units
Status
Withdrawn
Last Updated
5 years ago

Overview

Brief Summary

Need for perioperative blood transfusion is still high in certain types of oncological abdominal surgery. Allogeneic blood transfusion may be detrimental in cancer patients undergoing a potentially curative resection of malignant tumor, although the detailed mechanism of this effect is still under debate. We plan to evaluate whether a new, rotational thromboelastography-guided algorithm (ROTEM) to guide hemostatic resuscitation intra-operatively decreases the use of allogeneic blood products, the total amount of bleeding, transfusion related side effects, thromboembolic complications and costs. Its effect on each patient's post-operative hemostatic profile is also measured. 60 patients having a potentially curative pancreaticoduodenectomy (or resection of cauda of pancreas), total removal or partial resection of kidney and open radical cystectomy are recruited when an active blood loss of more than 1500 ml is estimated and/or measured and are randomized into two groups: one will be treated conventionally, ie. using massive transfusion protocol (MTP) if necessary, clinical judgement and conventional coagulation tests, the other treated using a ROTEM-based algorithm.

Registry
clinicaltrials.gov
Start Date
May 1, 2020
End Date
October 13, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age over 18, radical cystectomy, total or partial nephrectomy for malignant disease or pancreaticoduodenectomy planned and estimated intraoperative hemorrhage over 1500ml, written and informed consent

Exclusion Criteria

  • Known hemophilia or von Willebrandt's disease (treatment planned beforehand in collaboration with haematologist), unacceptance of allogeneic blood products (jehovah's witnesses).

Outcomes

Primary Outcomes

Number of transfused red blood cell (RBC) units

Time Frame: 24 hours after beginning of surgery

Red blood cell units transfused per patient during operation or up to 24 hours after beginning of surgery

Secondary Outcomes

  • Intensive care admissions(30 days after surgery)
  • Length of hospital stay(30 days after surgery)
  • Transfusion-related side effects(30 days after surgery)
  • Thromboembolic events(30 days after surgery)

Study Sites (1)

Loading locations...

Similar Trials